1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends


  • April 2018
  • 149 pages
  • ID: 5437166
  • Format: PDF
  • By Visiongain


Table of Contents

By Kinase Inhibitors, by Immunotherapeutic Agents, by Chemotherapeutic Agents, Tafinlar, Mekinist, Zelbroaf, Yervoy, Proleukin, Keytruda, PegIntron, Roferon-A, Dacarbazine, Temodar/Temodal and Leading Companies

Report Details
Melanoma Drugs - new study showing you trends, R&D progress, and predicted revenues
Where is the melanoma drugs market heading? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2028, discussing data, opportunities and prospects.
Our new 149-page report provides 161 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments.
You find prospects for key submarkets

In addition to analyses of the overall world market, you see revenue forecasts for these four submarkets to 2028:
- Chemotherapeutic melanoma drugs
- Kinase Inhibitors
- Immunotherapeutic melanoma drugs
- Other melanoma drugs
Drugs that can significantly increase disease-free and progression-free survival while also improving patient tolerance will achieve success. Combination therapies aimed at attacking melanoma from multiple angles will prove successful in providing added benefits to patients and manufacturers.
Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find the dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products

How will leading drugs perform to 2028 at the world level? How will promising products currently in the pipeline perform once they are launched? Our study forecasts sales of 9 melanoma products including these:
- Dabrafenib (Tafinlar)
- Trametinib (Mekinist)
- Vemurafenib (Zelboraf)
- Ipilimumab (Yervoy)
- PegIntron (Sylatron)
- Proleukin (Aldesleukin)
- Pembrolizumab (Keytruda)
- Dacarbzine (DTIC-Dome)
- Temodar/Temodal (Temozolomide)
Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?

In addition to analyses of the overall world market, you discover individual revenue forecasts for 20 national markets to 2028:
- US
- Canada
- Mexico
- Brazil
- Argentina
- Paraguay
- Bolivia
- France
- Germany
- UK
- Spain
- Italy
- Russia
- China
- Japan
- India
- Australia
- Thailand
- Middle East
- Africa
Our analyses show sustained growth, particularly for the markets with high predisposition factors to melanoma such as in Australia, Europe, and the Americas. New product approvals and the development of innovative targeted therapies will influence market growth.
Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.
Leading companies and potential for market growth
Overall world revenue for melanoma drugs will reach $89bn in 2018, our work forecasts. Rising demand for melanoma drugs, expanding healthcare coverage, recently launched therapies and a strong R&D pipeline will increase sales to 2028.

Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
- Novartis
- Bristol Myers Squibb
- Bayer
- Sanofi
- AstraZeneca
- Amgen
- Roche
- Merck & Co.
- Celgene

A company profile gives you the following information:
- Recent financial results
- company’s activities and outlook, including oncology product portfolios and pipelines
- Assessment of recent developments ’ mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development activities

What is happening in the R&D pipeline for melanoma drugs? You see developmental trends, gaining insight into the R&D pipeline for:
- Kinase inhibitors for melanoma
- Immunotherapeutic agents for melanoma
- Vaccines for melanoma
- Genetic therapies for melanoma
- Other therapies for melanoma treatment
What issues will affect the melanoma drugs market?

Our new report discusses issues and events affecting the melanoma drugs market. You will find discussions of many issues and developments, including:
- Reimbursement, regulations, patent expiries, generic competition
- Cost savings and efficiencies
- The use of biologics, targeted and combination therapies
- Understanding melanoma aetiology and progression
- Safety and patient compliance
- Clinical evidence supporting product efficacy
Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2018 to 2028.
How the Melanoma Drugs Market Forecast 2018-2028 report helps you

In summary our 149-page report gives you the following knowledge: 
- Revenue forecasts to 2028 for the overall melanoma drugs market and 4 submarkets’ discover the industry’s prospects, finding promising areas for investments and revenues 
- Predicted revenues for 9 melanoma drugs ’ discover prospects for leading products in the market and promising therapies in the pipeline, with forecasted revenues provided to 2028 
- Revenue forecast to 2028 for 20 leading national markets ’ US 
Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, France, Germany, UK, Spain, Italy, Russia, China, Japan, India, Australia, Thailand, Middle East and Africa 
- Evaluation of pipeline drugs ’ find the market potential for leading products currently in the development pipeline in each market segment 
- Assessment of 10 leading companies ’ hear about products, results and strategies, including recent activities and outlook for companies such as Merck, Novartis, GSK, Bristol Myers Squibb, and Roche 
- Discussion of what stimulates and restrains companies and the market 
- Prospects for established firms and those seeking to enter the market 
- Opinions from our survey, seeing interviews with industry authorities 

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020

Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020SummaryCyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC pipeline Target constitutes close to 32 molecules. ...

Transplant Diagnostics Market - Global Outlook and Forecast 2020-2025

Transplant Diagnostics Market - Global Outlook and Forecast 2020-2025

  • $ 3500
  • February 2020

The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 2019–2025.The following factors are likely to contribute to the growth of the transplant diagnostics ...

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019’; ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • February 2020
    5 pages
  • Therapy  

  • United Kingdom  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2020
    7 pages
  • Hormone  



  • Pakistan  

    United States  


View report >

Therapy Market in the US

  • February 2020
    101 pages
  • Therapy  

    Cystic Fibrosis  


  • United States  

View report >

Analgesic Market 5 days ago

Therapy Market 6 days ago


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on